In the early days of the coronavirus pandemic, many drugmakers saw major share price declines as investors got to grips with the likely impact on prescribing, d 16 November 2021
As the initial waves of the coronavirus pandemic hit in early 2020, pharma and biotech stocks saw major declines as investors digested the likely impact. 11 November 2021
As the pandemic broke, Cantabrigian pharma major AstraZeneca had the wind in its sales, with a rising stock price and a winning R&D formula. 25 October 2021
Since Donald Trump’s 2018 “American Patients First” plan, and long before, the issue of drug pricing in the USA has been both a lightning rod for strong opinion 12 October 2021
Of all the chief executives of the world’s major biopharmaceutical companies, the one who could be excused for spending the most sleepless nights so far in 2021 27 September 2021
With around a week to go until the annual congress of the European Society of Medical Oncology (ESMO), the event already boasts more than 19,000 participants fr 10 September 2021
All signs point to an M&A boom in late 2021 and throughout 2022. In this episode, Lance Minor, principal and national co-leader of the life sciences practice at 1 September 2021
These are billed as being exciting times for cell and gene therapies, but seasoned observers of the pharmaceutical industry would be forgiven for taking that bi 31 August 2021
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pat 18 August 2021
As the dust settles on this year’s Alzheimer’s Association International Conference (AAIC), the industry is left with a wealth of insight from some of the leadi 13 August 2021
It is often remarked that the usual development time for a new vaccine or therapeutic is well over a decade. In this context, the monthslong timeframe for compa 14 July 2021
The UK government’s Vaccines Taskforce (VTF) was primarily established to ensure that the UK population would have access to a clinically safe and effective vac 6 July 2021
A new report has claimed that rapid advances in therapy innovation, process technologies and macro changes will deliver a post-pandemic surge across the US phar 25 June 2021
The adjectives that accompanied the US approval of the first drug to treat Alzheimer’s disease in nearly two decades sought to sum up the apparent magnitude of 8 June 2021
The annual meeting of the American Society of Clinical Oncology (ASCO) kicks off online on 4 June, with more than 2,500 abstract presentations representing cutt 28 May 2021
The mere notion of the US government supporting any policies that might encourage pharmaceutical patents to be ignored would have seemed inconceivable only 18 m 17 May 2021
There has never been a better time to raise money for companies in the life sciences sector, according to Ben Long, partner at UK-headquartered private equity f 23 March 2021
“Companies are borderless,” said Mark Duxon, chief executive of Transpharmation, a contract research organization (CRO) that has now added a Polish site to its 26 February 2021
Whether politicians choose to accept it or not, the countries of the world are engaged in a race to vaccinate their populations against the novel coronavirus - 27 January 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.